[191] analyzed RUNX1 expression in a well-characterized cohort of women with morbid obesity and NAFLD and reported that hepatic RUNX1 expression increases in the first steps of NAFLD but decreases in advanced stages of the disease. This evidence concerns the gene RUNX1 and metabolic dysfunction-associated steatotic liver disease.